BR112021018540A2 - Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente - Google Patents
Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um pacienteInfo
- Publication number
- BR112021018540A2 BR112021018540A2 BR112021018540A BR112021018540A BR112021018540A2 BR 112021018540 A2 BR112021018540 A2 BR 112021018540A2 BR 112021018540 A BR112021018540 A BR 112021018540A BR 112021018540 A BR112021018540 A BR 112021018540A BR 112021018540 A2 BR112021018540 A2 BR 112021018540A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- pharmaceutical formulations
- forming
- breast
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820076P | 2019-03-18 | 2019-03-18 | |
| US201962942111P | 2019-11-30 | 2019-11-30 | |
| PCT/US2020/023066 WO2020190900A1 (en) | 2019-03-18 | 2020-03-17 | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021018540A2 true BR112021018540A2 (pt) | 2021-11-30 |
Family
ID=72521270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021018540A BR112021018540A2 (pt) | 2019-03-18 | 2020-03-17 | Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220362264A1 (https=) |
| EP (1) | EP3941478A4 (https=) |
| JP (1) | JP2022525425A (https=) |
| CN (1) | CN113825514A (https=) |
| AU (1) | AU2020240017A1 (https=) |
| BR (1) | BR112021018540A2 (https=) |
| CA (1) | CA3133620A1 (https=) |
| IL (1) | IL286416A (https=) |
| WO (1) | WO2020190900A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792292B2 (en) | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101738369B1 (ko) * | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | 핫 멜트 압출된 제어 방출 투여형 |
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| US20140287039A1 (en) * | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| EP3247334A1 (en) * | 2015-01-20 | 2017-11-29 | Merck Patent GmbH | Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer |
| WO2017037647A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical compositions of abiraterone |
| TWI717629B (zh) * | 2017-08-28 | 2021-02-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Cyp17抑制劑的藥物組合物及其製備方法 |
| WO2019060525A1 (en) * | 2017-09-22 | 2019-03-28 | Dispersol Technologies, Llc | PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF |
-
2020
- 2020-03-17 AU AU2020240017A patent/AU2020240017A1/en not_active Abandoned
- 2020-03-17 WO PCT/US2020/023066 patent/WO2020190900A1/en not_active Ceased
- 2020-03-17 BR BR112021018540A patent/BR112021018540A2/pt not_active IP Right Cessation
- 2020-03-17 JP JP2021556402A patent/JP2022525425A/ja active Pending
- 2020-03-17 CA CA3133620A patent/CA3133620A1/en active Pending
- 2020-03-17 US US17/437,144 patent/US20220362264A1/en not_active Abandoned
- 2020-03-17 EP EP20772679.5A patent/EP3941478A4/en not_active Withdrawn
- 2020-03-17 CN CN202080036072.5A patent/CN113825514A/zh active Pending
-
2021
- 2021-09-14 IL IL286416A patent/IL286416A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020240017A1 (en) | 2021-11-04 |
| US20220362264A1 (en) | 2022-11-17 |
| WO2020190900A1 (en) | 2020-09-24 |
| EP3941478A1 (en) | 2022-01-26 |
| JP2022525425A (ja) | 2022-05-13 |
| IL286416A (en) | 2021-10-31 |
| EP3941478A4 (en) | 2022-12-28 |
| WO2020190900A8 (en) | 2021-10-14 |
| CN113825514A (zh) | 2021-12-21 |
| CA3133620A1 (en) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010848A (es) | Composiciones y procedimientos para el tratamiento del cancer. | |
| BR112015023910A2 (pt) | terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer | |
| BR112021026854A2 (pt) | Extrato de cânhamo para tratamento da dor, câncer e epilepsia em animais | |
| BR212016030926U2 (pt) | conjugados de alvo e partículas e formulações dos mesmos | |
| MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| BR112018013853A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| BR112016014830A2 (pt) | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp | |
| MX2020004516A (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas. | |
| BR112019011199A2 (pt) | método para tratar um indivíduo que tem um câncer de próstata e kits | |
| BR112017009986A2 (pt) | métodos para tratar indivíduos com síndrome de prader-willi ou síndrome de smith-magenis | |
| AR115566A1 (es) | Composiciones y procedimientos para el tratamiento del cáncer | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2016006688A (es) | Inhibidores tetraciclicos de autotaxina. | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| BR112021018540A2 (pt) | Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente | |
| CY1125361T1 (el) | Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
| MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
| MX394957B (es) | Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". | |
| BR112021021787A2 (pt) | Terapias de combinação | |
| BR112018071363A2 (pt) | composições farmacêuticas orais de nicotinamida | |
| BR112015011099A2 (pt) | Composições e métodos para o tratamento de diplasia ectodérmica | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |